Here’s how readers responded to a You Make the Call question about a fit 72-year-old patient with very active myeloma.
Disclaimer: ASH does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this article is solely at your own risk.
I recommend switching to a carfilzomib-based regimen (with cyclophosphamide or even pomalidomide) to achieve disease control and then consider an autologous stem cell transplant.
Surbhi Sidana, MD